Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Akero Therapeutics Inc is a biotechnology business based in the US. Akero Therapeutics shares (AKRO) are listed on the NASDAQ and all prices are listed in US Dollars. Akero Therapeutics employs 28 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$21.52|
|52-week range||$17.66 - $34.87|
|50-day moving average||$22.80|
|200-day moving average||$24.83|
|Wall St. target price||$47.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.75|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||3.71%|
|1 month (2021-09-27)||-10.48%|
|3 months (2021-07-27)||0.56%|
|6 months (2021-04-27)||-29.97%|
|1 year (2020-10-26)||-18.05%|
|2 years (2019-10-25)||2.53%|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-33.88%|
|Return on equity TTM||-58.76%|
|Market capitalisation||$739.8 million|
TTM: trailing 12 months
There are currently 2.8 million Akero Therapeutics shares held short by investors – that's known as Akero Therapeutics's "short interest". This figure is 0.8% down from 2.8 million last month.
There are a few different ways that this level of interest in shorting Akero Therapeutics shares can be evaluated.
Akero Therapeutics's "short interest ratio" (SIR) is the quantity of Akero Therapeutics shares currently shorted divided by the average quantity of Akero Therapeutics shares traded daily (recently around 147144.58531432). Akero Therapeutics's SIR currently stands at 18.93. In other words for every 100,000 Akero Therapeutics shares traded daily on the market, roughly 18930 shares are currently held short.
However Akero Therapeutics's short interest can also be evaluated against the total number of Akero Therapeutics shares, or, against the total number of tradable Akero Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akero Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Akero Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1265% of the tradable shares (for every 100,000 tradable Akero Therapeutics shares, roughly 127 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Akero Therapeutics.
Find out more about how you can short Akero Therapeutics stock.
We're not expecting Akero Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Akero Therapeutics's shares have ranged in value from as little as $17.655 up to $34.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akero Therapeutics's is 0.5593. This would suggest that Akero Therapeutics's shares are less volatile than average (for this exchange).
Akero Therapeutics, Inc. , a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.